Hanall Biopharma (009420) Fundamentals 2026 — Revenue Analysis | SniperIQ
Hanall Biopharma (009420) is a KR-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of ₩2.44T, trading at ₩48000.00 on the KSC. This SniperIQ fundamentals page covers Hanall Biopharma's valuation, profitability (net margin -3.2%), revenue (₩155.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Hanall Biopharma's market cap?
Hanall Biopharma (009420) has a market capitalization of approximately ₩2.44T, trading at ₩48000.00 on the KSC. Market cap moves with the live share price.
What is Hanall Biopharma's P/E ratio?
Hanall Biopharma's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 15.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Hanall Biopharma?
Hanall Biopharma runs a net profit margin of -3.2%, a gross margin of 51.6%, and an operating margin of -0.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Hanall Biopharma generate?
Hanall Biopharma reported revenue of ₩155.2B for fiscal year 2025, with net income of -₩5.6B and earnings per share (EPS) of -111.55. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Hanall Biopharma pay a dividend?
Hanall Biopharma does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Hanall Biopharma financially healthy?
Hanall Biopharma carries a debt-to-equity ratio of 0.27x and a current ratio of 1.60x, with a market beta of 0.79. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Hanall Biopharma a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Hanall Biopharma (009420) the key facts are: market cap ₩2.44T, revenue ₩155.2B, 52-week range 25550-73000. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Hanall Biopharma's full fundamentals live
Get Hanall Biopharma's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.